"Trade Name (Agent)",Sponsor,"Date of BT Designation Disclosure","Approval Date",Indication,Category,"FDA Status"
"Imcivree (setmelanotide)","Rhythm Pharmaceutical, Inc.",1/7/2016,6/16/2022,"For chronic weight management in adult and pediatric patients 6 years of age and older with Bardet-Biedl Syndrome (BBS).",Other,"FDA Approval"
Gedatolisib,"Celcuity Inc. ",7/18/2022,,"Treatment of patients with HR+/HER2- metastatic breast cancer whose disease progressed during treatment with a CDK4/6 therapy and a non-steroidal aromatase inhibitor.",Cancer,"Designation Granted"
"Dupixent (dupilumab)","Regeneron Pharmaceuticals Inc.",10/1/2016,6/7/2022,"Treatment of adult and pediatric patients ages 6 months and older with moderateto-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.",Other,"FDA Approval"
"VIJOICE (alpelisib)","Novartis Pharmaceuticals Corp.",11/13/2019,4/5/2022,"Treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.",Cancer,"FDA Approval"
"Apretude (Cabotegravir)","ViiV Healthcare",11/17/2020,12/20/2021,"HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at-risk adults and pediatric patients 12 to less than 18 years of age weighing at least 35 kg.","Infectious Disease","FDA Approval"
"Oxbryta (voxelotor)"," Global Blood Therapeutics, Inc.",1/3/2018,12/17/2021,"Treatment of sickle cell disease in adults and pediatric patients 4 years of age and older.","Rare Inherited Disorders","FDA Approval"
"Oxbryta (voxelotor)"," Global Blood Therapeutics, Inc.",1/3/2018,12/17/2021,"Treatment of sickle cell disease in pediatric patients 4 years of age and older.","Rare Inherited Disorders","FDA Approval"
"Orencia (abatacept)","Bristol-Myers Squibb Co.",12/4/2019,12/15/2021,"Prevention of moderate to severe acute graft-versus-host disease (GvHD) in hematopoietic stem cell transplants from unrelated donors.",Other,"FDA Approval"
"Fyarro (ABI-009)","Aadi Bioscience Inc.",1/3/2019,11/22/2021,"Treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).",Cancer,"FDA Approval"
"CARVYKTI (ciltacabtagene autoleucel)","Janssen Pharmaceuticals Inc.",2022,2/28/2022,"Treatment of adult patients with relapsed or refractory multiple myeloma, who previously received a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and an anti-CD38 antibody.",Cancer,"FDA Approval"
"Dupixent (dupilumab)","Regeneron Pharmaceuticals Inc.",9/14/2020,5/20/2022," Treatment of patients 12 years and older with eosinophilic esophagitis (EoE).",Other,"FDA Approval"
"Tecartus (brexucabtagene autoleuce)","Kite Pharma Inc.",2016,7/24/2020,"Chimeric antigen receptor or CAR T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma or MCL.",Cancer,"FDA Approval"
Talquetamab,"Janssen Pharmaceuticals Inc.",6/29/2022,,"Treatment of adult patients with relapsed or refractory multiple myeloma, who have previously received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.",Cancer,"Designation Granted"
"Inaxaplin (VX-147)","Vertex Pharmaceuticals, Inc.",6/8/2022,,"Treatment for APOL1-mediated focal segmental glomerulosclerosis (FSGS).",Other,"Designation Granted"
"Efanesoctocog alfa","Sanofi and Sobi",6/1/2022,,"Treatment of people with hemophilia A.",Other,"Designation Granted"
TMB-001,"Timber Pharmaceuticals, Inc.",5/31/2022,,"Treatment of congenital ichthyosis (CI). ",Other,"Designation Granted"
Repotrectinib,"Turning Point Therapeutics, Inc.",5/10/2022,,"Treatment of patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) who have been previously treated with one ROS1 tyrosine kinase inhibitor and who have not received prior platinum-based chemotherapy.",Cancer,"Designation Granted"
"ENHERTU (fam-trastuzumab deruxtecan-nxki)","AstraZeneca and Daiichi Sankyo Co.",4/26/2022,5/4/2022,"Treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-negative) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.",Cancer,"FDA Approval"
"CMS I-neb",Zambon,4/21/2022,,"Treatment for the reduction in the incidence of pulmonary exacerbations in adult patients with non-cystic fibrosis bronchiectasis (NCFB) colonized with P. aeruginosa.",Other,"Designation Granted"
V116,"Merck & Co., Inc.",4/14/2022,,"Vaccine for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B in adults 18 years of age and older.","Infectious Disease","Designation Granted"
"EDSIVO™ (celiprolol)","Acer Therapeutics Inc.",4/4/2022,,"Treatment of patients with COL3A1-positive vascular Ehlers-Danlos syndrome (vEDS).",Other,"Designation Granted"
"PF-06928316 (RSVpreF)","Pfizer Inc.",3/24/2022,,"Vaccine for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age or older.","Infectious Disease","Designation Granted"
"PF-06928316 (RSVpreF)","Pfizer Inc.",03/02/2022,,"Vaccine for the prevention of RSV-associated lower respiratory tract illness in infants from birth up to six months of age by active immunization of pregnant women.","Infectious Disease","Designation Granted"
"BI 1015550","Boehringer Ingelheim",02/24/2022,,"Treatment of idiopathic pulmonary fibrosis (IPF).",Other,"Designation Granted"
"MVA-BN RSV","Bavarian Nordis A/S",2/14/2022,,"Active immunization for prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults aged 60 years or older.","Infectious Disease","Designation Granted"
"Farxiga® (dapagliflozin)",AstraZeneca,1/29/2022,,"Treatment of patients with chronic kidney disease (CKD) whether or not they have type 2 diabetes.",Other,"Designation Granted"
"DZD9008 (Sunvozertinib)","Dizal Pharmaceutical Co., Ltd.",1/27/2022,,"Treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.",Cancer,"Designation Granted"
CLN-081,"Cullinan Oncology, Inc.",1/04/2022,,"Treatment of patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) harboring epidermal growth factor (“EGFR”) exon 20 insertion mutations who have previously received platinum-based systemic chemotherapy.",Cancer,"Designation Granted"
"Vedotin (Teliso-V)","AbbVie Inc.",1/04/2022,,"Treatment of patients with advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy.",Cancer,"Designation Granted"
"Patritumab Deruxtecan (HER3-DXd)","Daiichi Sankyo Company, Ltd.",12/23/2021,,"Treatment of patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer (NSCLC) with disease progression on or after treatment with a third-generation tyrosine kinase inhibitor (TKI) and platinum-based therapies.",Cancer,"Designation Granted"
Aficamten,"Cytokinetics, Inc.",12/09/2021,,"Treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).",Cardiovascular,"Designation Granted"
Gantenerumab,"Genentech Inc.",10/08/2021,,"Treatment of people living with Alzheimer’s disease (AD).",Other,"Designation Granted"
"Tecartus (brexucabtagene autoleucel)","Kite Pharma Inc.",2017,10/01/2021,"Treatment of adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).",Cancer,"FDA Approval"
Repotrectinib,"Zai Lab Limited and Turning Point Therapeutics, Inc.",10/04/2021,,"Treatment of patients with advanced solid tumors that have an NTRK gene fusion who have progressed following treatment with one or two prior TRK tyrosine kinase inhibitors, with or without prior chemotherapy, and have no satisfactory alternative treatment",Cancer,"Designation Granted"
"ENHERTU (fam-trastuzumab deruxtecan-nxki)","AstraZeneca and Daiichi Sankyo Co.",10/04/2021,,"Treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.",Cancer,"Designation Granted"
"EXKIVITY (mobocertinib)","Takeda Pharmaceutical Company Ltd.",4/27/2020,9/15/2021,"Treatment of NSCLC Patients with EGFR Exon 20 Insertion Mutations",Cancer,"FDA Approval"
"JARDIANCE (empagliflozin)","Eli Lilly and Co.",9/09/2021,,"Investigational treatment of heart failure with preserved ejection fraction",Cardiovascular,"Designation Granted"
"Toripalimab in combination with Gemcitabine and Cisplatin","Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc.",8/12/2021,,"First-line treatment of recurrent or metastatic nasopharyngeal carcinoma",Cancer,"Designation Granted"
"Nexviazyme (avalglucosidase alfa-ngpt)",Sanofi/Genzyme,11/18/2020,8/06/2021,"Treatment of patients one year of age and older with late-onset Pompe disease.",Other,"FDA Approval"
Avexitide,"Eiger BioPharmaceuticals Inc.",8/05/2021,,"Treatment of congenital hyperinsulism (HI).",Other,"Designation Granted"
ARO-AAT,"Arrowhead Pharmaceuticals Inc.",7/29/2021,,"Treatment for the rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD).","Rare Inherited Disorders","Designation Granted"
TAK-994,"Takeda Pharmaceutical Company Ltd.",7/28/2021,,"Treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy type 1 (NT1).",Other,"Designation Granted"
"Venclexta (venetoclax)","Genentech Inc.",7/21/2021,,"Treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the revised International Prognostic Scoring System (IPSS-R).",Other,"Designation Granted"
"ALK-001 (C20-D3-vitamin A)","Alkeus Pharmaceuticals Inc.",7/14/2021,,"Treatment of Stargardt Disease.",Other,"Designation Granted"
ASP3772,"Affinivax Inc. and Astellas Pharma Inc.",7/13/2021,,"Vaccine candidate targeting Streptococcus pneumoniae designed to offer both B-cell (antibody) and T-cell immune protection.","Infectious Disease","Designation Granted"
VLA1553,"Valneva SE",7/07/2021,,"Chikungunya Vaccine","Infectious Disease","Designation Granted"
Orelabrutinib,"InnoCare Pharma Ltd.",6/28/2021,,"Treatment of relapsed or refractory mantle cell lymphoma (R/R MCL).",Cancer,"Designation Granted"
Adagrasib,"Mirata Therapeutics Inc.",6/25/2021,,"Treatment of non-small cell lung cancer (NSCLC) in patients harboring the KRASG12C mutation after systemic therapy.",Cancer,"Designation Granted"
Donanemab,"Eli Lilly and Co.",6/25/2021,,"Investigational antibody therapy for Alzheimer's disease (AD).",Other,"Designation Granted"
"Lecanemab (BAN2401)","Eisai Co. and Biogen Inc.",6/23/2021,,"Investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease.",Other,"Designation Granted"
"Pluvicto (Lu-PSMA-617)","Novartis Pharmaceuticals Corporation",6/16/2021,4/23/2022,"Treatment for advanced castration-resistant prostate cancer.",Cancer,"FDA Approval"
"Ayvakit (Avapritinib)","Blueprint Medicines Corporation",1/12/2021,6/16/2021,"Treatment for patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).",Other,"FDA Approval"
"VS-6766 in combination with Defactinib","Verastem, Inc",5/24/2021,,"Treatment of all patients with recurrent low-grade serous ovarian cancer (LGSOC) regardless of KRAS status after one or more prior lines of therapy, including platinum-based chemotherapy.",Cancer,"Designation Granted"
Rusfertide,"Protagonist Therapeutics, Inc.",6/03/2021,,"Treatment of patients with polycythemia vera (PV) for the reduction of erythrocytosis in those patients who do not require further treatment for thrombocytosis and/or leukocytosis.",Other,"Designation Granted"
Teclistamab,"Janssen Pharmaceuticals, Inc",6/01/2021,,"Treatment for patients with relapsed/refractory multiple myeloma.",Cancer,"Designation Granted"
Bemarituzumab,"Amgen Inc.",4/19/2021,,"Treatment for patients with fibroblast growth factor receptor 2b (FGFR2b) overexpressing and human epidermal growth factor receptor 2 (HER2)-negative metastatic and locally advanced gastric and gastroesophageal (GEJ) adenocarcinoma in combination with mod",Cancer,"Designation Granted"
TTP399,"vTv Therapeutics Inc.",4/13/2021,,"Adjunctive therapy to insulin for the treatment of type 1 diabetes",Other,"Designation Granted"
"Futibatinib (TAS-120)","Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd",4/01/2021,,"Treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR2 gene rearrangements, including gene fusions",Cancer,"Designation Granted"
"Parsaclisib (IBI376)","Innovent Biologics, Inc.",3/21/2021,,"Treatment of patients with relapsed/refractory follicular lymphoma (FL). IBI376 is a phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor originally discovered by Incyte. Innovent owns the rights to develop and commercialize Parsaclisib in greater China.",Cancer,"Designation Granted"
BXCL501,"BioXcel Therapeutics, Inc.",3/15/2021,,"Acute treatment of agitation associated with dementia",Other,"Designation Granted"
"Nulibry (fosdenopterin)","BridgeBio Pharma, Inc.",2/26/2021,2/26/2021,"Treatment for molybdenum Cofactor Deficiency (MoCD) Type A","Rare Inherited Disorders","FDA Approval"
"Cabozantinib (CABOMETYX®)","Exelixis, Inc.",2/25/2021,9/17/2021,"Treatment for patients with differentiated thyroid cancer (DTC) that has progressed following prior therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). ",Cancer,"FDA Approval"
Tipifarnib,"Kura Oncology, Inc.",2/24/2021,,"Treatment of patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma (HNSCC) with variant allele frequency ≥ 20% after disease progression on platinum-based chemotherapy.",Cancer,"Designation Granted"
"Tebentafusp (IMCgp100)",Immunocore,2/19/2021,1/25/2022,"Treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM).",Cancer,"FDA Approval"
"Scemblix (Asciminib)","Novartis International AG",2/08/2021,10/29/2021,"Treatment of adult patients with Ph+ CML in CP harboring the T315I mutation.",Cancer,"FDA Approval"
"Scemblix (Asciminib)","Novartis International AG",2/08/2021,10/29/2021,"Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs).",Cancer,"FDA Approval"
"Enhertu (trastuzumab deruxtecan)","AstraZeneca plc and Daiichi Sankyo Co.",5/11/2020,1/15/2021,"Treatment of adult patients with previously treated HER2 positive advanced gastric cancer",Cancer,"FDA Approval"
"DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)","Janssen Biotech, Inc.",2013,1/15/2021,"Treatment of adult patients with newly diagnosed light-chain (AL) amyloidosis.",Other,"FDA Approval"
"Ligelizumab (QGE031)","Novartis International AG",1/14/2021,,"Treatment of chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria (CIU), in patients who have an inadequate response to H1-antihistamine treatment.","Rare Inherited Disorders","Designation Granted"
"APL-106 (uproleselan)","Apollomics, Inc",1/07/2021,,"Treatment of relapsed/refractory acute myeloid leukemia (AML).",Cancer,"Designation Granted"
Chiauranib,"Shenzhen Chipscreen Biosciences Co., Ltd",1/05/2021,,"""Treatment of patients with small cell lung cancer (SCLC) with disease progression or recurrence after two lines of prior systematic chemotherapy.  """,Cancer,"Designation Granted"
"Tiragolumab in combination with Tecentriq","The Roche Group",1/05/2021,,"First-line treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression with no EGFR or ALK genomic tumour aberrations",Cancer,"Designation Granted"
"CNCT19 (CD19 CAR-T)","CASI Pharmaceuticals, Inc. ",12/23/2020,,"A potential CD19 CAR-T therapy for the treatment of adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)",Cancer,"Designation Granted"
"IO102 and IO103 with anti-PD-1 mAb","IO Biotech",12/15/2020,,"Patients with unresectable/ metastatic melanoma",Cancer,"Designation Granted"
"IO102 and IO103 with anti-PD-1 mAb","IO Biotech",12/15/2020,,"Patients with unresectable/ metastatic melanoma",Cancer,"Designation Granted"
"CUTX-101 (Copper Histidinate)","Cyprium Therapeutics, Inc.",12/15/2020,,"Treatment of Menkes Disease","Rare Inherited Disorders","Designation Granted"
"Blenrep (BELANTAMAB MAFODOTIN-BLMF)","GlaxoSmithKline Intellectual Property Development LTD England",11/02/2017,8/05/2020,"Treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent",Cancer,"FDA Approval"
"Avastin (Bevacizumab)","GENENTECH INC",7/18/2018,5/29/2020,"In combination with atezolizumab, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy",Cancer,"FDA Approval"
"Pegloprastide (AVB-620)","Avelas Biosciences",12/14/2020,,"Intraoperative detection and visualization of positive margins during breast cancer surgery.",Cancer,"Designation Granted"
Zanidatamab,"Zymeworks Inc.",11/30/2020,,"Treatment for patients with previously-treated HER2 gene-amplified biliary tract cancer (BTC).",Cancer,"Designation Granted"
Zanidatamab,"Zymeworks Inc.",11/30/2020,,"Treatment for patients with previously-treated HER2 gene-amplified biliary tract cancer (BTC).",Cancer,"Designation Granted"
Sotorasib,"Amgen Inc.",12/08/2020,,"Treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation, as determined by an FDA-approved test, following at least one prior systemic therapy.",Cancer,"Designation Granted"
Repotrectinib,"Turning Point Therapeutics Inc.",12/08/2020,,"""Treatment of patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) who have not been treated with a ROS1 tyrosine kinase inhibitor (TKI-naïve).  """,Cancer,"Designation Granted"
Olorofim," F2G Ltd",10/22/2020,,"Treatment of Central Nervous System (CNS) coccidioidomycosis refractory or otherwise unable to be treated with standard of care therapy","Infectious Disease","Designation Granted"
Vixarelimab,"Kiniksa Pharmaceuticals Ltd",11/16/2020,,"Treatment of pruritus associated with prurigo nodularis, a chronic inflammatory skin condition characterized by severely pruritic skin nodules",Other,"Designation Granted"
"Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn)","Regeneron Pharmaceuticals",11/19/2019,10/14/2020,"Treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients","Infectious Disease","FDA Approval"
"EBANGA ANSUVIMAB-ZYKL","Ridgeback Biotherapeutics LP",9/06/2019,12/21/2020,"Treatment for Ebola","Infectious Disease","FDA Approval"
Lanifibranor,Inventiva,10/12/2020,,"Treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS)",Other,"Designation Granted"
IMGN632,"ImmunoGen, Inc",10/05/2020,,"Treatment of relapsed or refractory blastic plasmacytoid dendritic cell neoplasm",Cancer,"Designation Granted"
"Farxiga® (dapagliflozin)",AstraZeneca ,10/02/2020,4/30/2021,"Patients with chronic kidney disease (CKD), with and without type 2 diabetes (T2D)",Other,"FDA Approval"
MPDL3280A,Genentech/Roche,2/01/2015,,"Non-small cell lung cancer",Cancer,"Designation Granted"
"Rindopepimut (Rintega)",Celldex,2/23/2015,,"Glioblastoma (GBM)",Cancer,"Designation Granted"
EBV-CTL,"Atara and MSKCC",3/02/2015,,"EBV-associated lymphoproliferative disease",Cancer,"Designation Granted"
Rucaparib,Clovis,4/06/2015,,"Ovarian cancer",Cancer,"Designation Granted"
"Viaskin Peanut",DBV,4/09/2015,,"Peanut allergy in children",Other,"Designation Granted"
"Olipudase alfa",Sanofi/Genzyme,6/04/2015,,"Niemann-Pick disease Type B","Rare Inherited Disorders","Designation Granted"
"Obeticholic acid (OCA)",Intercept,1/29/2015,,"Nonalcoholic steatohepatitis (NASH)",Other,"Designation Granted"
Ixazomib,Takeda,12/02/2014,,"Systemic light-chain (AL) amyloidosis",Other,"Designation Granted"
JCAR015,"Juno Therapeutics",11/24/2014,,ALL,Cancer,"Designation Granted"
SPK-RPE65,"Spark Therapeutics",11/06/2014,,"Inherited retinal dystrophy (IRD)","Rare Inherited Disorders","Designation Granted"
AP26113,"Ariad Pharmaceuticals Inc.",10/02/2014,,"ALK-positive NSCLC",Cancer,"Designation Granted"
"CRS-207 and GVAX",Aduro,7/21/2014,,"Pancreatic cancer",Cancer,"Designation Granted"
"Rociletinib (CO-1686)","Clovis Oncology",5/19/2014,,NSCLC,Cancer,"Designation Granted"
MYDICAR,Celladon ,4/10/2014,,"Heart failure",Cardiovascular,"Designation Granted"
"ACTEMRA (tocilizumab)",Genentech/Roche,6/10/2015,3/04/2021,"Systemic scerlosis",Other,"FDA Approval"
SER-109,Seres,6/12/2015,,"Clostridium difficile infection (CDI)","Infectious Disease","Designation Granted"
NI-0501,Novimmune,3/16/2016,,"Primary Hemophagocytic Lymphohistiocytosis (HLH)","Rare Inherited Disorders","Designation Granted"
"PKC412 (midostaurin)",Novartis,2/19/2016,,"Newly-diagnosed FLT3-mutated AML",Cancer,"Designation Granted"
"Durvalumab (MEDI4736)",AstraZeneca,2/17/2016,,"PD-L1+ inoperable/metastatic urothelial bladder cancer",Cancer,"Designation Granted"
"Affinity enhanced T-cell therapy",Adaptimmune,2/09/2016,,"NY-ESO in synovial sarcoma",Cancer,"Designation Granted"
"Rapastinel (GLYX-13)",Allergan,1/31/2016,,"Major Depressive Disorder (MDD)",Other,"Designation Granted"
Venetoclax,AbbVie/Roche,1/28/2016,,"AML combination therapy",Cancer,"Designation Granted"
"Lynparza (olaparib)",AstraZeneca,1/27/2016,,"Metastatic Castration Resistant Prostate Cancer",Cancer,"Designation Granted"
"VTS 270",Vtesse,1/06/2016,,"Niemann-Pick Type C1 Disease (NPC)","Rare Inherited Disorders","Designation Granted"
DX-2930 ,Dyax,7/07/2015,,"Hereditary angioedema (HAE)","Rare Inherited Disorders","Designation Granted"
BMS-663068,BMS,7/21/2015,,"HIV-1 in heavily treatment-experienced adult patients","Infectious Disease","Designation Granted"
RBX2660,"Rebiotix, Inc.",10/12/2015,,"Recurrent Clostridium difficile (C diff) infection","Infectious Disease","Designation Granted"
"Inotuzumab Ozogamicin",Pfizer,10/19/2015,,ALL,Cancer,"Designation Granted"
"Pembrolizumab (Keytruda)",Merck,11/02/2015,,"Microsatellite Instability-High (MSI-H) metastatic colorectal cancer (mCRC)",Cancer,"Designation Granted"
"BI 1482694","Boehringer Ingelheim",12/18/2015,,"Advanced/pre-treated EGFR mutation-positive NSCLC",Cancer,"Designation Granted"
OMS721,Omeros,6/13/2017,,"Immunoglobulin A (IgA) nephropathy",Other,"Designation Granted"
Burtomab,"Y-mAbs Therapeutics, Inc.",6/07/2017,,"Pediatric patients with relapsed or refractory neuroblastoma with central nervous system or leptomeningeal metastasis",Cancer,"Designation Granted"
Balovaptan,Roche,1/29/2018,,"Autism spectrum disorder (ASD)","Rare Inherited Disorders","Designation Granted"
GMI-1271,GlycoMimetics,5/17/2017,,"Adult Relapsed/Refractory Acute Myeloid Leukemia",Cancer,"Designation Granted"
Vonapanitase,"Proteon Therapeutics, Inc.",5/10/2017,,"Increasing arteriovenous fistula secondary patency (i.e., survival of the fistula without abandonment) and use for hemodialysis in patients on or expected to initiate hemodialysis",Other,"Designation Granted"
"Rethymic (RVT-802)",Enzyvant,4/14/2017,10/8/2021,"Treatment of pediatric patients with congenital athymia.","Rare Inherited Disorders","FDA Approval"
"Evkeeza (evinacumab-dgnb)","Regeneron Pharmaceuticals, Inc",4/07/2017,2/11/2021,"Homozygous familial hypercholesterolemia (HOFH)","Rare Inherited Disorders","FDA Approval"
"Toca 511 & Toca FC",Tocagen,2/23/2017,,"Recurrent high grade glioma",Cancer,"Designation Granted"
AMT-060,uniQure,1/20/2017,,"Hemophilia B","Rare Inherited Disorders","Designation Granted"
"Neridronic acid","Grünenthal and Abiogen Pharma",12/16/2016,,"Complex regional pain syndrome (CRPS)","Rare Inherited Disorders","Designation Granted"
ABT-530,"AbbVie Inc.",9/30/2016,,"genotype 1 HCV patients who have failed to respond to a previous therapy of direct acting antivirals (or DAAs)","Infectious Disease","Designation Granted"
"Tonmya (TNX-102 SL)","Tonix Pharmaceuticals",12/19/2016,,PTSD,Other,"Designation Granted"
"Imcivree (setmelanotide)","Rhythm Pharmaceutical, Inc.",1/7/2016,11/27/2020,"Pro-opiomelanocortin (POMC) deficiency obesity and obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway (the MC4 pathway)","Rare Inherited Disorders","FDA Approval"
"Livtencity (Maribavir)","Takeda Pharmaceutical Company Ltd.",1/08/2018,11/23/2021,"Treatment of adults and pediatric patients 12 years of age and older and weighing at least 35 kg with posttransplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.","Infectious Disease","FDA Approval"
"Upadacitinib (ABT-494)","AbbVie Inc.",1/09/2018,,"Adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy",Other,"Designation Granted"
"Lenvima (lenvatinib)","Merck and Eisai",1/09/2018,8/10/2021,"In combination with pembrolizumab for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).",Cancer,"FDA Approval"
"Avelumab in combination with Inlyta (axitinib)","EMD Serono and Pfizer",12/21/2017,,"Treatment-naïve patients with advanced renal cell carcinoma (RCC)",Cancer,"Designation Granted"
Monjuvi,MorpoSys,10/23/2017,7/31/2020,"Relapsed/Refractory DLBCL who are not eligible for high-dose chemotherapy and autologous stem-cell transplantation",Cancer,"FDA Approval"
"Valoctocogene Roxaparvovec",BioMarin,10/26/2017,,"Hemophilia A","Rare Inherited Disorders","Designation Granted"
DAS181,"Ansun BioPharma",10/10/2017,,"Treatment of lower respiratory tract parainfluenza virus (PIV) infection in immunocompromised patients","Infectious Disease","Designation Granted"
EB-101,"Abeona Therapeutics Inc",8/30/2017,,"Recessive Dystrophic Epidermolysis Bullosa (RDEB)",Other,"Designation Granted"
"Methylenedioxymethamphetamine (MDMA)",MAPS,8/28/2017,,PTSD,Other,"Designation Granted"
Venetoclax,Abbvie/Roche,8/01/2017,,"Elderly patients with previously untreated Acute Myeloid Leukemia (AML) who are ineligible for intensive chemotherapy",Cancer,"Designation Granted"
Acalabrutinib,AstraZeneca,8/01/2017,,"Mantle cell lymphoma for patients who have received at least one prior line of therapy",Cancer,"Designation Granted"
"Elbit Imaging","Gamida Cell",10/10/2016,,Nicord,Cancer,"Designation Granted"
"Alecensa (alectinib)",Roche,10/04/2016,,"Adult patients with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received prior treatment with an ALK inhibitor",Cancer,"Designation Granted"
Serelaxin ,Novartis,6/21/2013,,"Acute heart failure",Cardiovascular,"Designation Granted"
Drisapersen,GlaxoSmithKline/Prosensa,6/27/2013,,"Duchenne muscular dystrophy (DMD)","Rare Inherited Disorders","Designation Granted"
"BYM338 (Bimagrumab)",Novartis,8/20/2013,,"Sporadic inclusion body myositis (sIBM)",Other,"Designation Granted"
Entinostat,Syndax,9/11/2013,,"ER-positive metastatic breast cancer combination",Cancer,"Designation Granted"
Volasertib,"Boehringer Ingelheim",9/17/2013,,"AML combination therapy",Cancer,"Designation Granted"
Grazoprevir/Elbasvir,Merck,10/22/2013,,"Hepatitis C","Infectious Disease","Designation Rescinded"
"cPMP (ALXN1011)","Alexion Pharmaceuticals Inc.",10/24/2013,,"Molybdenum cofactor deficiency (MoCD) type A","Rare Inherited Disorders","Designation Granted"
Dabrafenib,GlaxoSmithKline,1/13/2014,,"NSCLC w/ BRAF mutation",Cancer,"Designation Granted"
Esketamine,J&J,1/21/2014,,"Treatment resistant depression",Other,"Designation Granted"
"Daclatasvir/asunaprevir combination",BMS,2/24/2014,,"Hepatitis C","Infectious Disease","Designation Rescinded"
"LIVMARLI (maralixibat)",Shire,6/13/2016,9/29/2021,"Progressive familial intrahepatic cholestasis type 2 (PFIC2)","Rare Inherited Disorders","FDA Approval"
SD101,Scioderm,4/29/2013,,"Epidermolysis bullosa",Other,"Designation Granted"
Daclatasvir,BMS,4/25/2013,,"Hepatitis C combination therapy","Infectious Disease","Designation Granted"
SL-401,"Stemline Therapeutics",8/23/2016,,"Treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) targeting the interleukin-3 receptor (CD123)","Rare Inherited Disorders","Designation Granted"
Esketamine,Janssen,8/16/2016,7/31/2020,"Major depressive disorder with imminent risk for suicide",Other,"FDA Approval"
Pracinostat,"MEI Pharma",8/01/2016,,"In combination with azacitidine of patients with newly diagnosed acute myeloid leukemia unfit for intensive chemotherapy",Cancer,"Designation Granted"
V920,Merck,7/25/2016,,"Ebola Zaire","Infectious Disease","Designation Granted"
SPK-9001,Pfizer/Spark,7/21/2016,,"Hemophilia B.","Rare Inherited Disorders","Designation Granted"
"Ivacaftor (Kalydeco)",Vertex,2014,12/29/2014,"CF monotherapy, patients 6 years or older with R117H mutationin CFTR gene","Rare Inherited Disorders","FDA Approval"
"Ivacaftor (Kalydeco)",Vertex,2014,3/17/2015,"CF monotherapy, patients 2 years and older with one of the following CFTR gene mutations: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, R117H","Rare Inherited Disorders","FDA Approval"
"SHP621 (budesonide oral suspension, or BOS)",Shire,6/13/2016,,"Eosinophilic esophagitis (EoE)","Rare Inherited Disorders","Designation Granted"
PVS-RIPO,"Duke Medicine",5/15/2016,,"Recurrent glioblastoma multiforme (GBM)",Cancer,"Designation Granted"
"Ivacaftor (Kalydeco)",Vertex,12/15/2012,,"CF combination therapy","Rare Inherited Disorders","Designation Granted"
"Imbruvica (ibrutinib)","Pharmacyclics LLC",2/12/2013,11/13/2013,"Patients with mantle cell lymphoma (MCL)",Cancer,"FDA Approval"
"Kalydeco (ivacaftor)","Vertex Pharmaceuticals Inc.",2013,2/21/2014,"Patients age 6 years and older with cystic fibrosis who have mutations in the CTFR gene","Rare Inherited Disorders","FDA Approval"
"Bexsero (Meningococcal Group B Vaccine)","Novartis Vaccines and Diagnostics, Inc.",4/07/2014,1/23/2015,"Active immunization to prevent invasive meningococcal disease caused by N. meningitidis serogroup B in individuals 10 through 25 years of age","Infectious Disease","FDA Approval"
"Trumenba (Meningococcal Group B Vaccine)","Pfizer Inc.",3/20/2014,10/29/2014,"Active immunization to prevent invasive meningococcal disease caused by N. meningitidis serogroup B in individuals 10 through 25 years of age","Infectious Disease","FDA Approval"
"Kisqali (ribociclib)","Novartis Pharmaceuticals Corp.",6/20/2018,7/18/2018,"In combination with fulvestrant for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy",Cancer,"FDA Approval"
AMT-601,"uniQure N.V.",6/28/2018,,"Patients with severe and moderately severe hemophilia B","Rare Inherited Disorders","Designation Granted"
"Zemdri (plazomicin)",Achaogen,5/23/2017,,"Antibacterials addressing multi-drug resistant (MDR) gram-negative infections",Other,"Designation Rescinded"
HTX-011,"Heron Therapeutics, Inc.",6/21/2018,,"Postoperative Pain Management",Other,"Designation Granted"
"Venclexta (venetoclax) + Rituximab","AbbVie Inc. and Genentech Inc.",1/20/2016,6/08/2018,"Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy",Cancer,"FDA Approval"
"Xalkori (crizotinib)","Pfizer Inc.",5/29/2018,1/14/2021,"Patients with relapsed or refractory systemic anaplastic large cell lymphoma that is anaplastic lymphoma kinase-positive",Cancer,"FDA Approval"
"Xalkori (crizotinib)","Pfizer Inc.",5/29/2018,,"Patients with metastatic non-small cell lung cancer with MET exon 14 alterations with disease progression on or after platinum-based chemotherapy",Cancer,"Designation Granted"
Tafamidis,"Pfizer Inc.",5/23/2018,,"Transthyretin Cardiomyopathy (ATTR-ACT)",Cardiovascular,"Designation Granted"
Lenti-D,"Bluebird bio Inc.",5/23/2018,,"Cerebral adrenoleukodystrophy","Rare Inherited Disorders","Designation Granted"
Pitolisant,"Harmony Biosciences",5/21/2018,,"Excessive daytime sleepiness and cataplexy in patients with narcolepsy",Other,"Designation Granted"
Quizartinib,"Daiichi Sankyo Company, Limited",8/01/2018,,"Adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML)",Cancer,"Designation Granted"
"Verzenio (abemaciclib)","Eli Lilly and Co.",10/08/2015,2/26/2018,"Adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy",Cancer,"FDA Approval"
"Enjaymo (sutimlimab-jome)","Bioverativ Inc.",3/06/2018,2/4/2022,"Indicated to decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD).",Other,"FDA Approval"
GC4419,"Galera Therapeutics",2/28/2018,,"Reduction of the duration, severity, and incidence of severe oral mucositis induced by radiation therapy",Other,"Designation Granted"
"Advantage Arrest™ Silver Diamine Fluoride 38%","Elevate Oral Care",11/03/2016,,"Arrest of tooth decay in children and adults",Other,"Designation Granted"
Larotrectinib,"Loxo Oncology, Inc.",7/13/2016,,"Unresectable or metastatic solid tumors with NTRK-fusion proteins in adult and pediatric patients who require systemic therapy and who have either progressed following prior treatment or who have no acceptable alternative treatments",Cancer,"Designation Granted"
"Nuplazid (pimavanserin)","Acadia Pharmaceuticals Inc.",2017,,"Patients with dementia-related psychosis (DRP)",Other,"Designation Granted"
PF-04965842,"Pfizer Inc.",2/14/2018,,"Patients with moderate-to-severe atopic dermatitis (AD)",Other,"Designation Granted"
SAGE-217,"Sage Therapeutics",2/07/2018,,"Patients with major depressive disorder (MDD)",Other,"Designation Granted"
"ZX008 (fenfluramine)","Zogenix, Inc.",2/06/2018,,"Patients who have seizures associated with Dravet syndrome",Other,"Designation Granted"
"Korsuva (difelikefalin)","Cara Therapeutics Inc.",6/22/2017,8/23/2021,"Treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD).",Other,"FDA Approval"
"Kymriah (CTL019)",Novartis,4/18/2017,,"Adult patients with relapsed and refractory diffuse large B-cell lymphoma, who have failed two or more prior therapies",Cancer,"Designation Granted"
"Balovaptan (RG7314)","Hoffman-La Roche Inc.",1/28/2018,,"A vasopressin 1a (V1a) receptor antagonist for patients with autism spectrum disorder (ASD)",Other,"Designation Granted"
"Trastuzumab Deruxtecan (DS-8201)","Daiichi Sankyo",8/29/2017,,"HER2-positive, locally advanced, or metastatic breast cancer who have been treated with trastuzumab (Herceptin) and pertuzumab (Perjeta) and have disease progression after ado-trastuzumab emtansine (T-DM1; Kadcyla)",Cancer,"Designation Granted"
"Oxlumo (lumasiran)","Alnylam Pharmaceuticals Inc.",3/12/2018,11/23/2020,"Primary Hyperoxaluria Type 1 (PH1)","Infectious Disease","FDA Approval"
"Kymriah (tisagenlecleucel)","Novartis Pharmaceutical Corp.",4/18/2017,5/1/2018,"Treatment of adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).",Cancer,"FDA Approval"
"Trumenba (Meningococcal Group B Vaccine)","Pfizer Inc.",4/23/2018,,"Active immunization to prevent invasive meningococcal disease caused by N. meningitidis serogroup B in individuals 1 through 9 years of age",,"Designation Granted"
OMS721,"Omeros Corporation",4/26/2018,,"Patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), specifically those patents who have persistent TMA despite modification of immunosupressive therapy",Other,"Designation Granted"
"Ribaxamase (SYN-004)","Synthetic Biologics, Inc.",5/11/2017,,"prevention of Clostridium difficile infection","Infectious Disease","Designation Rescinded"
Ketamine,"Johnson & Johnson",4/16/2018,,"Patients with depression",Other,"Designation Granted"
SPK-8011,"Spark Therapeutics Inc.",2/15/2018,,"Patients with hemophilia A.","Rare Inherited Disorders","Designation Granted"
"Pedmark (sodium thiosulfate)","Fennec Pharmaceuticals Inc.",3/27/2018,,"Prevention of cisplatin-related ototoxicity in pediatric patients with standard risk hepatoblastoma (SR-HB)",Other,"Designation Granted"
"ALIS (amikacin liposome inhalation suspension)","Insmed Inc.",3/29/2018,,"Adult patients with nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex",Other,"Designation Granted"
bb2121,"Bristol Myers Squibb and Bluebird Bio",11/04/2017,,"Patients with relapsed or refractory multiple myeloma",Cancer,"Designation Granted"
tab-cel,"Altara Biotherapeutics Inc.",2/15/2015,,"Patients with EBV+ PTLD following allogeneic hematopoietic stem cell transplant",Other,"Designation Granted"
PTI-428,"Proteostasis Therapeutics",3/16/2018,,"Cystic Fibrosis for patients with two copies of the F508del mutation — one from their mother and one from their father — who are receiving Vertex’s Orkambi (lumacaftor/ivacaftor)","Rare Inherited Disorders","Designation Granted"
"Ibrance (palbociclib)","Pfizer Inc.",2016,2/19/2016,"Patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy",Cancer,"FDA Approval"
"Keytruda (pembrolizumab)","Merck Sharp & Dohme Corp.",4/24/2013,12/18/2015,"Patients with unresectable or metastatic melanoma",Cancer,"FDA Approval"
"Opdivo (nivolumab)","Bristol-Myers Squibb Company",9/02/2015,10/09/2015,"Patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy",Cancer,"FDA Approval"
"Opdivo (nivolumab)","Bristol-Myers Squibb Company",9/26/2014,12/22/2014,"Patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600+, a BRAF inhibitor",Cancer,"FDA Approval"
"Kymriah (tisagenlecleucel)","Novartis Pharmaceuticals Corp.",7/07/2014,8/30/2017,"Pediatric and young adult patients (age 3-25 years) with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse",Cancer,"FDA Approval"
"Yescarta (axicabtagene ciloleucel)","Kite Pharma Inc.",12/07/2015,10/18/2017,"Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy",Cancer,"FDA Approval"
"Rapamune (sirolimus)","PF Prism CV",2015,5/28/2015,"Patients with lymphangioleiomyomatosis (LAM)",Other,"FDA Approval"
"Xalkori (crizotinib)","PF Prism CV",4/21/2015,3/11/2016,"Patients with non-small cell lung cancer whose tumors are ROS-1 positive",Cancer,"FDA Approval"
"Zykadia (ceritinib)","Novartis Pharmaceuticals Corp.",3/15/2013,4/29/2014,"Patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib",Cancer,"FDA Approval"
"Imbruvica (ibrutinib)","Pharmacyclics LLC",2/12/2013,1/29/2015,"Patients with Waldenstrom's macroglobulinemia (WM)",Cancer,"FDA Approval"
"Breyanzi (Lisocabtagene maraleucel)","Juno Therapeutics/Celgene",12/20/2016,2/05/2021,"Relapsed/refractory (r/r) aggressive large B-cell NHL, including diffuse large B-cell lymphoma (DLBCL), not otherwise specified (de novo or transformed from indolent lymphoma), Primary Mediastinal B-cell Lymphoma (PMBCL) or Grade 3B Follicular Lymphoma",Cancer,"FDA Approval"
"Promacta (eltrombopag)","Novartis Pharmaceuticals Corp.",11/16/2018,,"Low platelet counts in people exposed to radiation",Other,"Designation Granted"
NGX-101,NeuroRx,11/13/2018,,"Severe Bipolar Depression with Acute Suicidal Ideation & Behavior (ASIB) after initial stabilization with ketamine or other effective therapy",Other,"Designation Granted"
"Xolair (omalizumab)","Genentech, Inc.",8/13/2018,9/28/2018,"Prevention of severe allergic reactions following accidental exposure to one or more foods in people with allergies",Other,"FDA Approval"
"Andexxa (andexanet alfa)","Portola Pharmaceuticals, Inc.",11/25/2013,5/03/2018,"patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding",Cardiovascular,"FDA Approval"
"Olipudase Alfa",Sanofi/Genzyme,11/29/2018,,"Niemann-Pick disease Type B (NPB)","Rare Inherited Disorders","Designation Granted"
lonafarnib,"Eiger BioPharmaceuticals",11/19/2018,11/20/2020,"Patients with Hutchinson-Gilford progeria syndrome (HGPS_","Rare Inherited Disorders","FDA Approval"
MEDI8897,AstraZeneca,2/06/2019,,"Prevention of lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV)",Other,"Designation Granted"
"Vaxneuvance (V114)","Merck & Co., Inc.",1/28/2019,7/16/2021,"Prevention of invasive pneumococcal disease in adults 18 years and older caused by 15 serotypes.","Infectious Disease","FDA Approval"
"UKONIQ (umbralisib)","TG Therapeutics",1/28/2019,2/05/2021,"Adult patients with marginal zone lymphoma (MZL) who did not respond to at least one anti-CD20 therapy",Cancer,"FDA Approval"
CP101,"Finch Therapeutics Group, Inc.",2/09/2019,,"Patients with recurrent Clostridium difficile infection","Infectious Disease","Designation Granted"
"AT-GAA (ATB200 + AT2221)","Amicus Therapeutics",2/26/2019,,"Patients with late onset Pompe disease","Rare Inherited Disorders","Designation Granted"
"Psilocybin therapy","COMPASS Pathways",10/23/2018,,"Treatment-resistant Depression",Other,"Designation Granted"
Myrcludex,"MYR Pharma",10/23/2018,,"Chronic hepatitis delta (HDV) infection","Infectious Disease","Designation Granted"
LOXO-292,"Loxo Oncology, Inc.",10/16/2018,,"Patients with advanced RET fusion-positive thyroid cancer who require systemic therapy, have progressed following prior treatment, and have no acceptable alternative treatment options",Cancer,"Designation Granted"
"Poteligeo (mogamulizumab-kpkc)","Kyowa Kirin, Inc.",10/25/2017,8/08/2018,"Adult patients Sézary syndrome (SS) after at least one prior systemic therapy",Cancer,"FDA Approval"
"Danyelza (naxitamab-gqgk)","Y-mAbs Therapeutics, Inc.",8/23/2018,11/25/2020,"In combination with GM-CSF for patients with high risk neuroblastoma refractory to initial therapy or with incomplete response to salvage therapy in patients older than 12 months of age with persistent, refractory disease limited to bone marrow",Cancer,"FDA Approval"
LOXO-292,"Loxo Oncology, Inc.",9/05/2018,,"Patients with metastatic RET-fusion-positive non-small cell lung cancer; patients with RET-mutant medullary thyroid cancer",Cancer,"Designation Granted"
PF-06651600,"Pfizer Inc.",9/06/2018,,"Patients with alopecia areata",Other,"Designation Granted"
Tezepelumab,"AstraZeneca & Amgen Inc.",9/07/2018,,"Patients with severe asthma, without an eosinophilic phenotype, who are receiving inhaled corticosteroids/long-acting beta2-agonists with or without oral corticosteroids and additional asthma controllers",Other,"Designation Granted"
CA-008,"Concentric Analgesics, Inc.",9/11/2018,,"Patients needing long-lasting, non-opioid pain relief",Other,"Designation Granted"
"Prevnar 20 (PF-06482077)","Pfizer, Inc.",9/20/2018,6/08/2021,"Prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes","Infectious Disease","FDA Approval"
"Luxturna (voretigene neparvovec-rzyl)","Spark Therapeutics Inc.",9/24/2014,12/19/2017,"Patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy","Rare Inherited Disorders","FDA Approval"
"Rubraca (rucaparib)","Clovis Oncology",10/03/2018,,"BRCA1/BRCA2-mutated, metastatic, castration-resistant prostate cancer",Cancer,"Designation Granted"
"Hemlibra (emicizumab-kxwh)","Genentech Inc.",4/17/2018,10/04/2018,"Patients with hemophilia A without factor VIII inhibitors","Rare Inherited Disorders","FDA Approval"
"Rezurock (belumosudil)","Kadmon Holdings, Inc.",10/17/2018,7/16/2021,"Patients with chronic graft-versus-host disease (cGVHD) after failure of two or more lines of systemic therapy",Other,"FDA Approval"
"Braftovi (encorafenib) + Mektovi (binimetinib) + Erbitux (cetuximab)","Array BioPharma and Eli Lilly and Co.",8/07/2018,,"Patients with BRAF V600E-mutation metastatic colorectal caner following 1 or 2 prior lines of treatment in the metastatic setting",Cancer,"Designation Granted"
seladelpar,"CymaBay Therapeutics",2/20/2019,,"Patients with early stage primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA)",Other,"Designation Granted"
Avexitide,"Eiger BioPharmaceuticals, Inc.",6/17/2019,,"Post-bariatric hypoglycemia (PBH)",Other,"Designation Granted"
DCR-PHXC,"Dicerna Pharmaceuticals",7/15/2019,,"Primary hyperoxaluria type 1 (caused by a mutation in the AGXT gene)",Other,"Designation Granted"
"Peginterferon Lambda","Eiger Pharmaceuticals",8/20/2019,,"Hepatitis delta virus (HDV) infection","Infectious Disease","Designation Granted"
"NKTR-214 (bempegaldesleukin) with Opdivo (nivolumab)","Nektar Therapeutics",8/23/2019,,"Untreated melanoma patients with either metastatic disease or who are unable to undergo surgery",Cancer,"Designation Granted"
Nirogacestat,"SpringWorks Therapeutics, Inc.",8/29/2019,,"Adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis",Cancer,"Designation Granted"
"Tepotinib (Tepmetko)",Merck,9/11/2019,2/03/2021,"Patients with metastatic non-small cell lung cancer (NSCLC) harboring a MET exon 14 skipping alteration who have progressed following platinum-based chemotherapy",Cancer,"FDA Approval"
"Cotellic (cobimetinib)","Memorial Sloan Kettering Cancer Center",10/03/2019,,"Adult patients with histiocytic neoplasms who do not harbor a BRAF V600 mutation","Rare Inherited Disorders","Designation Granted"
"Zejula (niraparib)","Janssen Pharmaceutica",10/03/2019,,"Patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer (CRPC) who have previously received taxane chemotherapy and androgen receptor (AR)–targeted therapy",Cancer,"Designation Granted"
"Trikafta (elexacaftor/ivacaftor/tezacaftor)","Vertex Pharmaceuticals Inc.",5/01/2018,10/21/2019,"Patients 12 years and older with cystic fibrosis who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene","Rare Inherited Disorders","FDA Approval"
"Givlaari (givosiran)","Alnylam Pharmaceuticals Inc.",5/30/2017,11/20/2019,"Adult patients with acute hepatic porphyria (AHP)","Rare Inherited Disorders","FDA Approval"
"Jakafi (Ruxolitinib)",Incyte,6/23/2016,5/28/2019,"Patients aged 12 years and older with steroid-refractory acute graft versus-host disease (GVHD)",Other,"FDA Approval"
"Aliqopa (copanlisib)",Bayer,5/30/2019,,"Adults patients with relapsed marginal zone lymphoma (MZL) who have received at least 2 prior therapies",Cancer,"Designation Granted"
"Oliceridine (TRV130)","Trevena, Inc.",2/22/2016,,"Moderate-to-Severe Acute Pain",Other,"Designation Rescinded"
AXS-05,"Axsome Therapeutics, Inc.",3/27/2019,,"Major Depressive Disorder (MDD)","Rare Inherited Disorders","Designation Granted"
PB2452,"PhaseBio Pharmaceuticals",4/08/2019,,"Reversal agent for the antiplatelet drug ticagrelor",Other,"Designation Granted"
SER-109,"Seres Therapeutics, Inc.",4/29/2019,,"Recurrent C. difficile infection","Rare Inherited Disorders","Designation Granted"
elafibranor,Genfit,4/19/2019,,"Patients with primary biliary cholangitis (PBC)",Other,"Designation Granted"
LJPC-0118,"La Jolla Pharmaceutical Company",4/24/2019,,"Patients with severe malaria","Infectious Disease","Designation Granted"
"enfortumab vedotin","Astellas Pharma US, Inc. and Seattle Genetics, Inc.",3/26/2018,,"Patients with locally advanced or metastatic urothelial carcinoma",Cancer,"Designation Granted"
"Zolgensma (onasemnogene abeparvovec-xioi)",AveXis,7/20/2016,5/24/2019,"Spinal muscular atrophy (SMA) Type 1 in children less than two years old",Other,"FDA Approval"
LN-145,"Iovance Biotherapeutics, Inc.",5/22/2019,,"Patients with recurrent, metastatic, or persistent cervical cancer who have progressed on or after chemotherapy",Cancer,"Designation Granted"
"Gavreto (Pralsentinib)","Blueprint Medicines Corporation",2/26/2019,9/04/2020,"Patients with RET fusion-positive NSCLC that has progressed on platinum-based chemotherapy",Cancer,"FDA Approval"
"Vitrakvi (larotrectinib)","Bayer Healthcare Pharmaceuticals Inc.",7/13/2016,11/26/2018,"Adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion who have no satisfactory alternative treatments or that have progressed following treatment",Cancer,"FDA Approval"
"Promacta (eltrombopag)","Novartis Pharmaceuticals Corp.",1/04/2018,11/16/2018,"First-line treatment for adults and pediatric patients two years and older with SAA in combination with standard immunosuppressive therapy (IST)","Rare Inherited Disorders","FDA Approval"
"Adcetris (brentuximab vedotin)","Seattle Genetics Inc.",11/15/2018,11/16/2018,"Adult patients with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL) in combination with cyclophosphamide, doxorubicin, and prednisone",Cancer,"FDA Approval"
"Lorbrena (lorlatinib)","Pfizer Inc.",4/27/2017,11/02/2018,"Patients with ALK-positive metastatic NSCLC whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or alectinib or ceritinib",Cancer,"FDA Approval"
"Gamifant (emapalumab-Izsg)","Swedish Orphan Biovitrum AB (Publ.)",2018,11/20/2018,"Adult and pediatric patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy","Rare Inherited Disorders","FDA Approval"
"Firdapse (amifampridine)","Catalyst Pharmaceuticals Inc.",8/27/2013,11/28/2018,"Adult patients with Lambert–Eaton myasthenic syndrome (LEMS)",Other,"FDA Approval"
"Keytruda (pembrolizumab)","Merck Sharp & Dohme Corp",7/01/2017,12/19/2018,"Adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC)",Cancer,"FDA Approval"
"Elzonris (tagraxofusp)","Stemline Therapeutics, Inc.",6/15/2018,12/21/2018,"Adults and children aged 2 years and older with blastic plasmacytoid dendritic cell neoplasm (BPDCN)",Cancer,"FDA Approval"
"Kisquali Femara Co-Pack (letrozole and ribociclib)","Novartis Pharmaceuticals Corp.",1/10/2018,2/13/2019,"Treatment of pre/perimenopausal women with HR-positive, HER2- negative advanced or metastatic breast cancer",Cancer,"FDA Approval"
"Spravato (esketamine)","Janssen Pharmaceuticals, Inc.",11/15/2013,3/05/2019,"Patients with treatment-resistant depression",Other,"FDA Approval"
"Dupixent (Dupilumab)","Regeneron Pharmaceuticals Inc.",10/01/2016,3/11/2019,"Patients 12 to less than 18 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable",Other,"FDA Approval"
"Libtayo (cemiplimab-rwlc)","Regeneron Pharmaceuticals Inc.",9/08/2017,9/28/2018,"Patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation",Cancer,"FDA Approval"
"Arikayce (amikacin liposome inhalation suspension)","Insmed Inc.",6/17/2014,9/28/2018,"Treatment in a limited population of patients with Mycobacterium avium complex (MAC) lung disease who do not respond to conventional treatment","Infectious Disease","FDA Approval"
"Takhzyro (lanadelumab-flyo)","Dyax Corp.",7/02/2015,8/23/2018,"Prevention of attacks of hereditary angioedema (HAE) in people 12 years of age and older","Rare Inherited Disorders","FDA Approval"
"Keytruda (pembrolizumab)","Merck Sharp & Dohme Corp.",2017,6/13/2018,"Adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more prior lines of therapy",Cancer,"FDA Approval"
"Opdivo (nivolumab)","Bristol-Myers Squibb Company",2/10/2018,6/10/2018,"Patients 12 years of age and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan",Cancer,"FDA Approval"
"Yervoy (ipilimumab)","Bristol-Myers Squibb Company",2/10/2018,7/10/2018,"Patients 12 years of age and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan",Cancer,"FDA Approval"
"Kisqali (ribociclib)","Novartis Pharmaceuticals Corp.",6/20/2018,7/18/2018,"In combination with an aromatase inhibitor for pre/perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy",Cancer,"FDA Approval"
"Krintafel (tafenoquine)","GlaxoSmithKline Intellectual Property Development LTD England",12/18/2013,7/20/2018,"For the radical cure (prevention of relapse) of plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax","Infectious Disease","FDA Approval"
"Azedra (iobenguane I 131)","Progenics Pharmaceuticals Inc.",7/28/2015,7/30/2018,"Adult and pediatric patients (12 years and older) with iobenguane scan-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL) who require systemic anticancer therapy",Cancer,"FDA Approval"
"Poteligeo (mogamulizumab-kpkc)","Kyowa Kirin, Inc.",8/25/2017,8/08/2018,"Adult patients with relapsed or refractory mycosis fungoides (MF) or Sezary syndrome after at least one prior systemic therapy",Cancer,"FDA Approval"
"Orkambi (lumacaftor/ivacaftor)","Vertex Pharmaceuticals Inc.",3/12/2018,8/07/2018,"Treatment of cystic fibrosis (CF) in patients 2 years and older, homozygous for the F508del-CFTR mutation in the CFTR gene","Rare Inherited Disorders","FDA Approval"
"Onpattro (patisiran)","Alnylam Pharmaceuticals Inc.",2/02/2018,8/10/2018,"Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults","Rare Inherited Disorders","FDA Approval"
"Oxervate (cenegermin-bkbj ophthalmic solution)","Dompe Farmaceutici SpA",11/30/2017,8/22/2018,"Patients with neurotrophic keratitis (NK)",Other,"FDA Approval"
"Venclexta (venetoclax)","AbbVie Inc.",10/25/2017,11/21/2018,"In combination with azacitidine, decitabine, or low-dose cytarabine for adults aged 75 and older with treatment-naive acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy",Cancer,"FDA Approval"
"Zulresso (Brexanolone)","Sage Therapeutics Inc.",9/06/2016,3/19/2019,"Postpartum depression (PPD)",Other,"FDA Approval"
"Brukinsa (zanubrutinib)","BeiGene USA, Inc.",1/16/2019,11/14/2019,"Patients with mantle cell lymphoma (MCL) who have received at least one prior therapy",Cancer,"FDA Approval"
"Adakveo (crizanlizumab-tmca)","Novartis Pharmaceuticals Corporation",1/08/2019,11/15/2019,"To reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease","Rare Inherited Disorders","FDA Approval"
"Calquence (acalabrutinib)",AstraZeneca,8/14/2019,11/21/2019,"Adult patients with untreated chronic lymphocytic leukemia (CLL)",Cancer,"FDA Approval"
"Calquence (acalabrutinib)",AstraZeneca,8/14/2019,11/21/2019,"Adult patients with relapsed or refractory chronic lymphocytic leukemia",Cancer,"FDA Approval"
"Padcev (enfortumab vedotin-ejfv)","Astellas Pharma US, Inc.",3/26/2018,12/18/2019,"Patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting",Cancer,"FDA Approval"
omidubicel,"Gamida Cell Ltd.",10/11/2016,,"Patients with high-risk blood cancers who do not have a suitable matched donor",Cancer,"Designation Granted"
"Tibosovo (ivosidenib)","Servier Pharmaceuticals",3/27/2019,5/25/2022,"In combination with azacitidine or as monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",Cancer,"FDA Approval"
"Cosela (trilaciclib)","Cosela to G1 Therapeutics, Inc.",8/07/2019,2/12/2021,"Reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer.",Cancer,"FDA Approval"
"B38M (JNJ‐4528)","Legend Biotech + Janssen Global Services",12/06/2019,,"Patients with previously treated multiple myeloma",Cancer,"Designation Granted"
"Enhertu (fam-trastuzumab deruxtecan-nxki)","Daiichi Sankyo Co.",5/08/2019,12/20/2019,"Adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting",Cancer,"FDA Approval"
"Oxbryta (voxelotor)","Global Blood Therapeutics, Inc.",1/09/2018,11/25/2019,"Sickle cell disease (SCD) in patients 12 years and older","Rare Inherited Disorders","FDA Approval"
"Lenvima (lenvatinib)","Eisai Co.",8/01/2018,9/17/2019,"In combination with pembrolizumab for the treatment of patients with previously advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy and are not candidates for surgery or radiation",Cancer,"FDA Approval"
"Keytruda (pembrolizumab)","Merck Sharp & Dohme Corp",8/01/2018,9/17/2019,"In combination with lenvatinib for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy and are not candidates for surgery or radiation",Cancer,"FDA Approval"
"Ibrance (palbociclib)","Pfizer Inc.",2017,4/04/2019,"In combination with an aromatase inhibitor, or in combination with fulvestrant, for treatment of male patients with advanced or metastatic breast cancer",Cancer,"FDA Approval"
"Balversa (erdafitinib)","Janssen Biotech, Inc.",3/15/2018,4/12/2019,"Adult patients with locally advanced or metastatic urothelial carcinoma (mUC) that has susceptible FGFR3 or FGFR2 genetic alterations and progressed during at least on line of platinum-containing chemotherapy",Cancer,"FDA Approval"
"Keytruda (pembrolizumab)","Merck Sharpe & Dohme Corp.",12/10/2017,4/19/2019,"In combination with axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC)",Cancer,"FDA Approval"
"Vyndaquel (tafamidis meglumine)","Foldrx Pharmaceuticals, Inc. Sub. Pfizer, Inc.",5/24/2018,5/03/2019,"Patients with cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular related hospitalization",Other,"FDA Approval"
"Kadcyla (ado-trastuzumab emtansine)","Genentech Inc.",2/05/2019,5/03/2019,"Adjuvant treatment of patients with HER2-positive early breast cancer who have residual disease after neoadjuvant taxane and trastuzumab-based treatment",Cancer,"FDA Approval"
"Bavencio (avelumab)","EMD Serono Inc.",12/22/2017,5/14/2019,"In combination with Inlyta (axitinib) for first-line treatment of patients with advanced renal cell carcinoma (RCC)",Cancer,"FDA Approval"
"Venclexta (venetoclax)","AbbVie Inc.",3/15/2019,5/15/2019,"In combination with obinutuzumab for treatment of previously untreated patients with chronic lymphocytic leukemia (1L CLL) or small lymphocytic lymphoma (SLL)",Cancer,"FDA Approval"
"Emgality (galcanezumab)","Eli Lilly & Company",11/15/2018,6/04/2019,"Episodic cluster headache in adults","Rare Inherited Disorders","FDA Approval"
"Polivy (polatuzumab vedotin-piiq)","Genentech, Inc.",12/10/2017,6/10/2019,"In combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, after at least two prior therapies",Cancer,"FDA Approval"
"Turalio (pexidartinib)","Daiichi Sankyo",10/30/2015,8/02/2019,"Adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery",Cancer,"FDA Approval"
"Rozlytrek (entrectinib)","Genentech, Inc.",5/15/2017,8/15/2019,"Adult and pediatric patients 12 years of age and older with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic, and have progressed following treatment or have no alternative treatment option",Cancer,"FDA Approval"
"Actemra (tocilizumab)","Genentech Inc.",10/05/2016,5/22/2017,"Adult patients with giant cell arteritis (GCA)","Rare Inherited Disorders","FDA Approval"
"Keytruda (pembrolizumab)","Merck Sharp & Dohme Corp.",2017,5/18/2017,"Patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neo- or neo-adjuvant treatment with platinum-containing chemotherapy",Cancer,"FDA Approval"
"Kisqali Femara Co-Pack (letrozole and ribociclib)","Novartis Pharmaceuticals Corp.",8/02/2016,5/04/2017,"Postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced metastatic breast cancer",Cancer,"FDA Approval"
"Imfinzi (durvalumab)",AstraZeneca,2/16/2016,5/01/2017,"Patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neo- or adjuvant treatment with platinum-containing chemo",Cancer,"FDA Approval"
"Keytruda (pembrolizumab)","Merck Sharp & Dohme Corp.",2017,5/23/2017,"Adult and pediatric patients with unresectable or metastatic MSI-H or mismatch repair deficient solid tumors that have progressed following prior treatment or metastatic, MSI-H or mistmatch repair colorectal cancer that has progressed following treatment",Cancer,"FDA Approval"
"Zykadia (ceritinib)","Novartis Pharmaceuticals Corp.",2017,5/26/2017,"Patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA approved test",Cancer,"FDA Approval"
"Mekinist (trametinib)","Novartis Pharmaceuticals Corp.",2017,6/22/2017,"Patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by and FDA-approved test",Cancer,"FDA Approval"
"Tafinlar (dabrafenib)","Novartis Pharmaceuticals Corp.",7/24/2015,6/22/2017,"Patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by and FDA-approved test",Cancer,"FDA Approval"
"Imbruvica (ibrutinib)","Pharmacyclics LLC",6/29/2016,8/02/2017,"Adult patients with chronic graft-versus-host-disease (cGVHD) after failure of one or more lines of systemic therapy","Infectious Disease","FDA Approval"
"VYXEOS (cytarabine and daunorubicin)","Celator Pharmaceuticals Inc.",5/20/2016,8/03/2017,"Adult patients with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)",Cancer,"FDA Approval"
"Mavyret (glecaprevir & pibrentasvir)","AbbVie Inc.",9/30/2016,8/03/2017,"Patients with chronic hepatitis C virus (HCV) genotype (GT) 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis; and also for patients with HCV GT1 infection previously treated w/ HCV NS5A or NS3/4A inhibitor but not both","Infectious Disease","FDA Approval"
"Rydapt (midostaurin)","Novartis Pharmaceuticals Corp.",1/29/2016,4/28/2017,"Adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation",Cancer,"FDA Approval"
"Alunbrig (brigatinib)","Ariad Pharmaceuticals Inc.",10/01/2014,4/28/2017,"Patients with anaplastic lymphoma kinase (ALK)-positive mestastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib",Cancer,"FDA Approval"
"Ingrezza (valbenazine)","Neurocrine Biosciences Inc.",10/30/2014,4/11/2017,"Patients with tardive dyskinesia",Other,"FDA Approval"
"Darzalex (daratumumab)","Janssen Biotech Inc.",7/26/2016,11/21/2016,"Patients with multiple myeloma who have received at least one prior therapy, in combination with bortezomib and dexamethasone",Cancer,"FDA Approval"
"Rubraca (rucaparib)","Clovis Oncology Inc.",4/06/2016,12/19/2016,"Patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies",Cancer,"FDA Approval"
"Opdivo (nivolumab)","Bristol-Myers Squibb Company",6/27/2016,2/02/2017,"Patients with locally advanced or metastatic urothelial carcinoma in patients who have disease progression during or following platinum-containing chemotherapy; have disease progression within 12 months neo- or neoadjuvant treatment with platinum chemo",Cancer,"FDA Approval"
"Kisqali (ribociclib)","Novartis Pharmaceuticals Corp.",8/03/2016,3/13/2017,"Postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer as initial endocrine-based therapy",Cancer,"FDA Approval"
"Keytruda (pembrolizumab)","Merck Sharp & Dohme Corp.",4/18/2016,3/14/2017,"Patients with hematological malignancies: Hodgkin Lymphoma",Cancer,"FDA Approval"
"Bavencio (avelumab)","EMD Serono Inc.",11/18/2015,3/23/2017,"Adult and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC)",Cancer,"FDA Approval"
"Zejula (niraparib)","Tesaro Inc.",10/14/2016,3/27/2017,"Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy",Cancer,"FDA Approval"
"Dupixent (dupilumab)","Regeneron Pharmaceuticals Inc.",11/20/2014,3/28/2017,"Adult patients with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable",Other,"FDA Approval"
"Ocrevus (ocrelizumab)","Genentech Inc.",2/17/2016,3/28/2017,"Adult patients with primary progressive forms of multiple sclerosis","Rare Inherited Disorders","FDA Approval"
"Ibrance (palbociclib)","Pfizer Inc.",2017,3/31/2017,"Postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor as initial endocrine-based therapy",Cancer,"FDA Approval"
"Brineura (cerliponase alfa)","Biomarin Pharmaceutical Inc.",8/27/2015,4/27/2017,"Pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency","Rare Inherited Disorders","FDA Approval"
"Besponsa (inotuzumab ozogamicin)","Wyeth Pharmaceuticals LLC",2017,8/17/2017,"Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)",Cancer,"FDA Approval"
"Opdivo (nivolumab)","Bristol-Myers Squibb Company",2/16/2018,4/16/2018,"In combination with ipilimumab, for treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma (RCC",Cancer,"FDA Approval"
"Yervoy (ipilimumab)","Bristol-Myers Squibb Company",2/16/2018,4/16/2018,"In combination with nivolumab, for treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma (RCC)",Cancer,"FDA Approval"
"Crysvita (burosumab)","Kyowa Kirin Inc.",6/28/2016,4/17/2018,"Patients aged 1 year and older with x-linked hypophosphatemia (XLH)","Rare Inherited Disorders","FDA Approval"
"Tagrisso (osimertinib)",AstraZeneca,10/09/2017,4/18/2018,"First-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions of L858R substitution mutations, as detected by an FDA approved test",Cancer,"FDA Approval"
"Tafinlar (dabrafenib)","Novartis Pharmaceuticals Corp.",10/23/2017,4/30/2018,"In combination with trametinib for the adjuvant treatment of patients with stage III melanoma with a BRAF V600E or V600K mutation, as detected by and FDA-approved test, and involvement of lymph node(s), following complete resection",Cancer,"FDA Approval"
"Mekinist (trametinib)","Novartis Pharmaceuticals Corp.",10/23/2017,4/30/2018,"In combination with dabrafenib for the adjuvant treatment of patients with stage III melanoma with a BRAF V600E or V600K mutation, as detected by and FDA-approved test, and involvement of lymph node(s), following complete resection",Cancer,"FDA Approval"
"Mekinist (trametinib)","Novartis Pharmaceuticals Corp.",10/23/2017,5/04/2018,"In combination with dabrafenib  for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options",Cancer,"FDA Approval"
"Tafinlar (dabrafenib)","Novartis Pharmaceuticals Corp.",10/23/2017,5/04/2018,"In combination with trametinib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options",Cancer,"FDA Approval"
"Gilenya (fingolimod)","Novartis Pharmaceuticals Corp.",12/18/2017,5/11/2018,"Patients with relapsing multiple sclerosis (MS) to include pediatric patients 10 years of age and above","Rare Inherited Disorders","FDA Approval"
"Rituximab (Rituxan)","Genentech Inc.",3/24/2017,6/07/2018,"Patients with moderate to severe pemphigus vulgaris (PV)","Rare Inherited Disorders","FDA Approval"
"Venclexta (venetoclax)","AbbVie Inc.",2018,6/08/2018,"Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma, with or without 17p deletion, who have received at least one prior therapy",Cancer,"FDA Approval"
"Adcetris (brentuximab vedotin)","Seattle Genetics Inc.",10/15/2017,3/20/2018,"Treatment for adult patients with previously untreated Stage III or IV classical Hodgkin Lymphoma, in combination with chemotherapy",Cancer,"FDA Approval"
"Austedo (deutetrabenazine)","Teva Branded Pharmaceutical Products R and D Inc.",11/09/2015,8/30/2017,"Patients with tardive dyskinesia",Other,"FDA Approval"
"Verzenio (abemaciclib)","Eli Lilly and Co.",10/08/2015,9/28/2017,"Patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting",Cancer,"FDA Approval"
"Calquence (acalabrutinib)",AstraZeneca,8/01/2017,10/31/2017,"Adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy",Cancer,"FDA Approval"
"Alecensa (alectinib)","Hoffman-La Roche Inc.",9/23/2013,11/06/2017,"Patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test",Cancer,"FDA Approval"
"Zelboraf (vemurafenib)","Hoffmann La Roche Inc.",8/07/2017,11/06/2017,"Patients with Erdheim-Chester disease (ECD) with a BRAF V600 mutation",Other,"FDA Approval"
"Prevymis (letermovir)","Merck Sharp & Dohme Corp.",2/27/2017,11/08/2017,"Prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT)","Infectious Disease","FDA Approval"
"Adcetris (brentuximab vedotin)","Seattle Genetics Inc.",10/02/2017,11/09/2017,"Patients with primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides who have received prior systemic therapy",Cancer,"FDA Approval"
"Hemlibra (emicizumab-kxwh)","Genentech Inc.",9/04/2015,11/16/2017,"Prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A with factor VIII inhibitors","Rare Inherited Disorders","FDA Approval"
"Opdivo (nivolumab)","Bristol-Myers Squibb Company",10/17/2017,12/20/2017,"Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection",Cancer,"FDA Approval"
"Symdeko (tezacaftor and ivacaftor)","Vertex Pharmaceuticals Inc.",1/28/2014,2/12/2018,"Patients with cystic fibrosis aged 12 year and older who are homozygous for the F508del mutation who have at least one mutation in the CTFR gene that is responsive to Symdeko based on in vitro data or clinical evidence","Rare Inherited Disorders","FDA Approval"
"Imfinzi (durvalumab)",AstraZeneca,7/31/2017,2/16/2018,"Patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy",Cancer,"FDA Approval"
"Trogarzo (ibalizumab)","Theratechnologies Inc.",2/27/2015,3/06/2018,"Treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen","Infectious Disease","FDA Approval"
"Ibrance (palbociclib)","Pfizer Inc.",4/10/2013,2/03/2015,"Postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced metastatic breast cancer as initial endocrine-based therapy for their metastatic disease",Cancer,"FDA Approval"
"Kalydeco (ivacaftor)","Vertex Pharmaceuticals Inc.",2014,12/29/2014,"Patients age 6 years and older with cystic fibrosis who have the R117H mutation in the CF transmembrane conductance regulator (CTFR gene)","Rare Inherited Disorders","FDA Approval"
"Opdivo (nivolumab)","Bristol-Myers Squibb Company",2/15/2013,12/22/2014,"Patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor",Cancer,"FDA Approval"
"Viekira Pak (ombitasvir, paritaprevir, ritonavir)","AbbVie Inc.",5/06/2013,12/19/2014,"Patients with genotype 1 chronic hepatitis C virus (HCV) infection including those with compensated cirrhosis","Infectious Disease","FDA Approval"
"Blincyto (blinatumomab)","Amgen Inc.",7/01/2014,12/03/2014,"Patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)",Cancer,"FDA Approval"
"Xuriden (uridine triacetate)","Wellstat Therapeutics Corp.",4/30/2014,9/04/2015,"Patients with hereditary orotic aciduria","Rare Inherited Disorders","FDA Approval"
"Lucentis (ranibizumab)","Genentech Inc.",12/15/2014,2/06/2015,"Treatment of Diabetic Retinopathy (DR) in patients with Diabetic Macula Edema (DME)",Other,"FDA Approval"
"Kalydeco (ivacaftor)","Vertex Pharmaceuticals Inc.",12/15/2012,3/17/2015,"Patients 2 years and older with cystic fibrosis and have that one of the following CFTR gene mutations: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, R117H","Rare Inherited Disorders","FDA Approval"
"Eylea (aflibercept)","Regeneron Pharmaceuticals Inc.",9/16/2014,3/25/2015,"Treatment of diabetic retinopathy (DR) in patients with diabetic macular edema (DME)",Other,"FDA Approval"
"Orkambi (lumacaftor and ivacaftor)","Vertex Pharmaceuticals Inc.",1/29/2014,7/02/2015,"Patients 12 years and older with cystic fibrosis who are homozygous for the F508del mutation in the CFTR gene","Rare Inherited Disorders","FDA Approval"
"Technivie (ombitasvir, paritaprevir, ritonavir)","AbbVie Inc.",6/30/2014,7/24/2015,"Patients with genotype 4 chronic hepatitis C viruse (HCV) infection without cirrhosis","Infectious Disease","FDA Approval"
"Esbriet (pirfenidone)","Genentech Inc.",7/17/2014,10/15/2014,"Patients with idiopathic pulmonary fibrosis (IPF)",Other,"FDA Approval"
"Ofev (nintedanib)","Boehringer Ingelheim Pharmaceuticals Inc.",7/16/2014,10/15/2014,"Patients with idiopathic pulmonary fibrosis (IPF)",Other,"FDA Approval"
"Harvoni (sofosbuvir/ledipasvir)","Gilead Sciences Inc.",7/25/2013,10/10/2014,"Patients with chronic hepatitis C, genotype 1 infection","Infectious Disease","FDA Approval"
"Keytruda (pembrolizumab)","Merck Sharpe & Dohme Corp.",7/15/2019,,"Patients with hepatocellular carcinoma",Cancer,"Designation Granted"
"Cibinqo (Abrocitinib)","Pfizer Inc.",2/14/2018,1/14/2022,"Treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable",Other,"FDA Approval"
Exebacase,"ContraFect Corporation",2/24/2020,,"Patients with MRSA bacteremia, including right-sided endocarditis, when used in conjunction with standard of care antibiotics","Infectious Disease","Designation Granted"
"Braftovi (encorafenib)","Array BioPharma Inc.",2019,4/08/2020,"In combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, detected by an FDA-approved test, after prior therapy",Cancer,"FDA Approval"
"Gazyva (obinutuzumab)","Genentech Inc.",5/15/2013,11/01/2013,"Patients with previously untreated chronic lymphocytic leukemia in combination with chlorambucil",Cancer,"FDA Approval"
"Arzerra (ofatumumab)","Novartis Pharmaceuticals Corp.",9/13/2013,4/17/2014,"Previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate",Cancer,"FDA Approval"
"Zydelig (idelalisib)","Gilead Sciences Inc.",11/18/2013,7/23/2014,"Patients with relapsed chronic lymphocytic leukemia, in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities",Cancer,"FDA Approval"
"Imbruvica (ibrutinib)","Pharmacyclics LLC",4/08/2013,7/28/2014,"Patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and CLL with 17p deletion",Cancer,"FDA Approval"
"Promacta (eltrombopag)","Novartis Pharmaceuticals Corp.",2/03/2014,8/26/2014,"Cytopenias in patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy ",Other,"FDA Approval"
"Keytruda (pembrolizumab)","Merck Sharp & Dohme Corp",2014,9/04/2014,"Patients with unresectable or metastatic melanoma & disease progression following ipilimumab and, if BRAF V600 mutation positibr, a BRAF inhibitor",Cancer,"FDA Approval"
"Sovaldi (sofosbuvir)","Gilead Sciences Inc.",10/25/2013,12/06/2013,"Patients with chronic hepatitis C infection","Infectious Disease","FDA Approval"
"Keytruda (pembrolizumab)","Merck Sharp & Dohme Corp.",10/27/2014,10/02/2015,"Patients with metastatic, PD-L1 positive, non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy",Cancer,"FDA Approval"
"Opdivo (nivolumab)","Bristol-Myers Squibb Company",5/14/2014,5/17/2016,"Patients with Hodgkin Lymphoma",Cancer,"FDA Approval"
"Tecentriq (atezolizumab)","Genentech Inc.",5/22/2014,5/18/2016,"Patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neo- or adjuvant treatment with platinum-containing chemotherapy",Cancer,"FDA Approval"
"Epclusa (sofosbuvir and velpatasvir)","Gilead Sciences Inc.",10/28/2015,6/28/2016,"Adult patients with chronic hepatitis C virus (HCV) genotypes 1,2,3,4,5, or 6 infection: -without cirrhosis or with compensated cirrhosis -with decompensated cirrhosis for use in combination with ribavirin","Infectious Disease","FDA Approval"
"Ilaris (canakinumab)","Novartis Pharmaceuticals Corp.",4/27/2016,9/23/2016,"Patients with Tumor Necrosis Factor-Receptor Associated Periodic Syndrome (TRAPS)","Rare Inherited Disorders","FDA Approval"
"Darzalex (daratumumab)","Janssen Biotech Inc.",2016,11/21/2016,"Patients with multiple myeloma who have received at least one prior therapy, in combination with lenalidomide and dexamethasone",Cancer,"FDA Approval"
"Ilaris (canakinumab)","Novartis Pharmaceuticals Corp.",4/27/2016,9/23/2016,"Patients with Familial Mediterranean Fever (FMF)","Rare Inherited Disorders","FDA Approval"
"Orkambi (lumacaftor and ivacaftor)","Vertex Pharmaceuticals Inc.",2016,9/28/2016,"Patients ages 6-11 with cystic fibrosis who are homozygous for the F508del mutation in the CFTR gene","Rare Inherited Disorders","FDA Approval"
"Tecentriq (atezolizumab)","Genentech Inc.",5/31/2014,10/18/2016,"Patients with metastatic non-small cell lung cancer who have disease progression during or following platinum-containing chemotherapy",Cancer,"FDA Approval"
"Lartruvo (olaratumab)","Eli Lilly and Company",6/08/2015,10/19/2016,"Patients with soft tissue sarcoma (STS) with a histologic subtype, in combination with doxorubicin, for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery",Cancer,"FDA Approval"
"Opdivo (nivolumab)","Bristol-Myers Squibb Company",4/25/2016,11/10/2016,"Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum based therapy",Cancer,"FDA Approval"
"Zepatier (grazoprevir and elbasvir)","Merck Sharp & Dohme Corp.",4/08/2015,1/28/2016,"Adult patients with chronic hepatitis C virus (HCV) genotypes 1 and 4 infections","Infectious Disease","FDA Approval"
"Lenvima (lenvatinib mesylatel)","Eisai Inc.",7/29/2015,5/13/2016,"Patients with renal cell carcinoma (RCC): in combination with evorlimus, for patients with advanced RCC following one prior anti-angiogenic therapy",Cancer,"FDA Approval"
"Nuplazid (pimavanserin)","Acadia Pharmaceuticals Inc.",9/02/2014,4/29/2016,"Patients with hallucinations and delusions associated with Parkinson's disease psychosis",Other,"FDA Approval"
"Praxbind (idarucizumab)","Boehringer Ingelheim Pharmaceuticals Inc.",6/26/2014,10/16/2015,"Patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding",Other,"FDA Approval"
"Strensiq (asfotase alfa)","Alexion Pharmaceuticals Inc.",5/28/2013,10/23/2015,"Patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP)","Rare Inherited Disorders","FDA Approval"
"Tagrisso (osimertinib) ",AstraZeneca,4/24/2014,11/13/2015,"Patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive-non-small-cell lung cancer (NSCLC), as detected by and FDA approved test who have progressed on or after EGFR TKI therapy",Cancer,"FDA Approval"
"Darzalex (daratumumab)","Janssen Biotech Inc.",5/01/2013,11/16/2015,"Patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent",Cancer,"FDA Approval"
"Opdivo (nivolumab)","Bristol-Myers Squibb Company",9/16/2015,11/23/2015,"Patients with advanced renal cell carcinoma who have received prior antiangiogenic therapy",Cancer,"FDA Approval"
"Empliciti (elotuzumab)","Bristol-Myers Squibb Company",5/19/2014,11/30/2015,"Patients with multiple myeloma who have received one to three prior therapies",Cancer,"FDA Approval"
"Kanuma (sebelipase alfa)","Alexion Pharmaceuticals Inc.",5/20/2013,12/08/2015,"Patients with a diagnosis of lysosomal acid lipase (LAL) deficiency","Rare Inherited Disorders","FDA Approval"
"Alecensa (alectinib)","Hoffman La Roche Inc.",6/15/2013,12/11/2015,"Patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), who have progressed on or are intolerant to crizotinib",Cancer,"FDA Approval"
"Ilaris (canakinumab)","Novartis Pharmaceuticals Corp.",4/27/2016,9/23/2016,"Patients with Hyperimmunoglobulin D Syndrome (HIDS)","Rare Inherited Disorders","FDA Approval"
"Venclexta (venetoclax)","AbbVie Inc.",5/06/2015,4/11/2016,"Patients with chronic lymphocytic leukemia (CLL) with 17p deletion who have received at least one prior therapy",Cancer,"FDA Approval"
"Cabotetyx (cabozantinib)","Exelixis Inc.",8/24/2015,4/25/2016,"Patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy",Cancer,"FDA Approval"
"Pemazyre (pemigatinib)","Incyte Corporation",2020,2020,"Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test",Cancer,"FDA Approval"
"Jelmyto (mitomycin)","UroGen Pharma",10/31/2018,4/15/2020,"Treatment of adult patients with lowgrade upper tract urothelial cancer",Cancer,"FDA Approval"
"Opdivo (nivolumab)","Bristol-Myers Squibb Company",2020,3/10/2020,"In combination with ipilimumab, for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib",Cancer,"FDA Approval"
"Yervoy (ipilimumab)","Bristol-Myers Squibb Company",11/11/2019,3/10/2020,"In combination with nivolumab, for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib",Cancer,"FDA Approval"
"Retevmo (selpercatinib)","Loxo Oncology, Inc.",10/15/2018,5/08/2020,"Patients with metastatic, RET-fusion-positive non-small-cell lung cancer (NSCLC) who require systemic therapy and progressed following anti PD-L1 therapy or platinum-based chemotherapy plus an anti-PD-1 therapy",Cancer,"FDA Approval"
"TABRECTA (capmatinib)","Novartis Pharmaceuticals Corporation",9/06/2019,5/06/2020,"Treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test",Cancer,"FDA Approval"
"Sacituzumab Govitecan-hziy","Immunomedics INC",2/05/2016,4/22/2020,"Treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease",Cancer,"FDA Approval"
CTP-543,"Concert Pharmaceuticals",7/08/2020,,"Treatment of Alopecia Areata","Rare Inherited Disorders","Designation Granted"
"Ofev (nintedanib)","Boehringer Ingelheim Pharmaceuticals",10/10/2019,3/09/2020,"Chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype","Rare Inherited Disorders","FDA Approval"
"Zynteglo (betibeglogene autotemcel (beti-cel; formerly LentiGlobin™))",BlueBird,2/02/2015,,Beta-thalassemia,"Rare Inherited Disorders","Designation Granted"
"Brensocatib (INS1007)","Insmed Incorporated",6/08/2020,,"Treatment of bronchiectasis and other inflammatory diseases and  of adult patients with non-cystic fibrosis bronchiectasis (NCFBE) for reducing exacerbation","Rare Inherited Disorders","Designation Granted"
"HSV Pritelivir (AIC316)","Anti-infective Cures GmbH",6/05/2020,,"Treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised adults",Other,"Designation Granted"
"Neuromodulation therapy (NTX100)","Noctrix Health",6/02/2020,,"Treatment of adults with primary moderate-severe Restless Legs Syndrome (RLS) who are refractory to medications",Other,"Designation Granted"
"Psilocybin formulation (Comp 360)","Compass Pathways",10/23/2018,,"Treatment-resistant depression",Other,"Designation Granted"
"Olumiant (Baricitinib)","Eli Lilly and Company + Incyte Corporation",3/16/2020,6/13/2022,"Treatment of adult patients with severe alopecia areata.",Other,"FDA Approval"
"Esbriet (pirfenidone)","Hoffman-La Roche Inc.",3/03/2020,,"Patients with unclassifiable interstitial lung disease",Other,"Designation Granted"
Sotatercept,"Acceleron Pharma",4/08/2020,,"Patients with pulmonary arterial hypertension",Cardiovascular,"Designation Granted"
"ABECMA (idecabtagene vicleucel)","Bristol-Myers Squibb Company",11/15/2017,3/26/2021,"Adult patients with relapsed or refractory multiple myeloma",Cancer,"FDA Approval"
AXS-05,"Axsome Therapeutics, Inc.",3/15/2019,,"Patients with major depressive disorder that is resistant to current treatments",Other,"Designation Granted"
JNJ-6372,"Janssen Biotech, Inc.",3/10/2020,,"Patients with EGFR-positive metastatic non-small cell lung cancer who harbor exon 20 insertion mutations, and whose disease has progressed on or after platinum-based chemotherapy",Cancer,"Designation Granted"
APR-246,"Aprea Therapeutics",1/30/2020,,"Treatment of patients with myelodysplastic syndromes with a susceptible TP53 mutation",Cancer,"Designation Granted"
"Olorofim (F901318)","F2G The Rare Fungal Disease Company",11/13/2019,,"Treatment of invasive mold infections in patients w limited or no treatment options, including aspergillosis refractory or intolerant to currently available therapy, & infections due to Lomentospora prolificans, Scedosporium, and Scopulariopsis species",Other,"Designation Granted"
CD20xCD3,"F. Hoffmann-La Roche AG",7/14/2020,,"Treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma who have received at least two prior systemic therapies",Cancer,"Designation Granted"
Padcev,"Astellas Pharma US, Inc.",2/20/2020,,"In combination with Keytruda for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting",Cancer,"Designation Granted"
ER-004,Esperare,7/06/2020,,"Investigational Prenatal Treatment ER-004 In X-Linked Hypohidrotic Ectodermal Dysplasia","Rare Inherited Disorders","Designation Granted"
TLX250-CDX,"Telix Pharmaceuticals",7/01/2020,,"Renal cancer imaging product",Cancer,"Designation Granted"
AXS-05,"Axsome Therapeutics",6/26/2020,,"Treatment of Alzheimer’s disease agitation, major depressive disorder, and other central nervous system (CNS) disorders",Other,"Designation Granted"
Brensocatib,"Insmed Incorporated",6/18/2020,,"Treatment for bronchiectasis","Rare Inherited Disorders","Designation Granted"
"Omidubicel (formerly known as NiCord®)","Gamida Cell (Emmes)",10/11/2016,,"Treatment opportunity for patients who need an allogeneic bone marrow transplant. Cellular therapy in Phase 3 development as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution",Cancer,"Designation Granted"
"Viaskin® Peanut","DBV Therapies",4/09/2015,,"Treatment for patients suffering from life threatening food allergies",Other,"Designation Granted"
NRX-101,NeuroRx,11/13/2018,,"Treatment of Severe Bipolar Depression with Acute Suicidal Ideation & Behavior (ASIB)",Other,"Designation Granted"
"ARCALYST (rilonacept)",Kiniksa,11/20/2019,3/18/2021,"Treatment of recurrent pericarditis",Cardiovascular,"FDA Approval"
"Palforzia (Arachis hypogaea)",Aimmune,6/18/2015,1/31/2020,"An oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut.",Other,"FDA Approval"
"Uplinza (inebilizumab-cdon)","Viela Bio",4/18/2019,6/11/2020,"Patients with neuromyelitis optica spectrum disorder (NMOSD)","Rare Inherited Disorders","FDA Approval"
"Tecentriq (atezolizumab)","Genentech Inc.",7/18/2018,5/29/2020,"In combination with bevacizumab, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy",Cancer,"FDA Approval"
"Ayvakit (avapritinib)","Blueprint Medicines Corporation",6/01/2017,1/09/2020,"Patients with unresectable or metastatic GIST harboring the PDGFRα D842V mutation",Cancer,"FDA Approval"
"TEPEZZA (TEPROTUMUMABTRBW)","HORIZON THERAPEUTICS IRELAND DAC",2020,1/21/2020,"Treatment of thyroid eye disease",Other,"FDA Approval"
AXS-12,"Axsome Therapeutics",8/05/2020,,"Treatment of cataplexy in patients with narcolepsy.",Other,"Designation Rescinded"
Pevonedistat,"Takeda Pharmaceutical Company",7/30/2020,,"Treatment of patients with higher-risk myelodysplastic syndromes (HR-MDS)",Cancer,"Designation Granted"
"Bavencio (avelumab)","Merck Sharpe & Dohme Corp.",4/09/2020,7/01/2020,"Patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy",Cancer,"FDA Approval"
"Tagrisso (osimertinib)",AstraZeneca,7/30/2020,12/18/2020,"Adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent.",Cancer,"FDA Approval"
MK-6482,"Merck Sharpe & Dohme Corp.",7/29/2020,,"Treatment of patients with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC) with nonmetastatic RCC tumors less than three centimeters in size, unless immediate surgery is required.",Cancer,"Designation Granted"
"Mavacamten (MYK-461)",MyoKardia,7/23/2020,4/28/2022,"Treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM).","Rare Inherited Disorders","FDA Approval"
"Rukobia (fostemsavir)","ViiV Healthcare",7/21/2015,7/02/2020,"Antiretroviral medication for adults living with HIV who have tried multiple HIV medications and whose HIV infection cannot be successfully treated with other therapies because of resistance, intolerance or safety considerations.","Infectious Disease","FDA Approval"
"Koselugo (Selumetinib)","AstraZeneca Plc and Merck & Co., Inc.",4/01/2019,4/10/2020,"Treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)","Rare Inherited Disorders","FDA Approval"
"TUKYSA (tucatinib)","SEATTLE GENETICS INC",2019,4/17/2020,"In combination with trastuzumab and capecitabine, for the treatment of adult patients with advanced unresectable or metastatic HER2- positive breast cancer, including patients with brain metastases, who have received one or more prior antiHER2-based regim",Cancer,"FDA Approval"
"Enspryng (satralizumab-mwge)","Genentech, Inc.",12/20/2018,8/14/2020,"Subcutaneous treatment for adults living with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD).","Rare Inherited Disorders","FDA Approval"
Artesunate,"AMIVAS LLC",2020,5/26/2020,"Initial treatment of severe malaria in adult and pediatric patients",Other,"FDA Approval"
"Qinlock (Ripretinib)","DECIPHERA PHARMACEUTICALS LLC",2020,5/15/2020,"Treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib",Cancer,"FDA Approval"
